Fax: (011) 617 3138 3130
Incidence and evidence for evaluation, prevention, and management within a prospective surveillance model of care
Article first published online: 6 APR 2012
Copyright © 2012 American Cancer Society
Supplement: A Prospective Surveillance Model for Rehabilitation for Women With Breast Cancer
Volume 118, Issue Supplement 8, pages 2237–2249, 15 April 2012
How to Cite
Hayes, S. C., Johansson, K., Stout, N. L., Prosnitz, R., Armer, J. M., Gabram, S. and Schmitz, K. H. (2012), Upper-body morbidity after breast cancer. Cancer, 118: 2237–2249. doi: 10.1002/cncr.27467
The articles in this supplement were commissioned based on presentations and deliberations at a Roundtable Meeting on a Prospective Model of Care for Breast Cancer Rehabilitation, held February 24-25, 2011, at the American Cancer Society National Home Office, in Atlanta, Georgia.
The opinions or views expressed in this supplement are those of the authors, and do not necessarily reflect the opinions or recommendations of the editors or the American Cancer Society. The views expressed in this article are those of the authors and do not reflect the official positions or views of the Department of Defense, the US Navy, or the US Government.
A Prospective Surveillance Model for Rehabilitation for Women With Breast Cancer, Supplement to Cancer
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
- Issue published online: 6 APR 2012
- Article first published online: 6 APR 2012
- Manuscript Accepted: 7 NOV 2011
- Manuscript Received: 17 OCT 2011
- breast cancer;
- upper-body morbidity;
The purpose of this paper is to review the incidence of upper-body morbidity (arm and breast symptoms, impairments, and lymphedema), methods for diagnosis, and prevention and treatment strategies. It was also the purpose to highlight the evidence base for integration of prospective surveillance for upper-body morbidity within standard clinical care of women with breast cancer. Between 10% and 64% of women report upper-body symptoms between 6 months and 3 years after breast cancer, and approximately 20% develop lymphedema. Symptoms remain common into longer-term survivorship, and although lymphedema may be transient for some, those who present with mild lymphedema are at increased risk of developing moderate to severe lymphedema. The etiology of morbidity seems to be multifactorial, with the most consistent risk factors being those associated with extent of treatment. However, known risk factors cannot reliably distinguish between those who will and will not develop upper-body morbidity. Upper-body morbidity may be treatable with physical therapy. There is also evidence in support of integrating regular surveillance for upper-body morbidity into the routine care provided to women with breast cancer, with early diagnosis potentially contributing to more effective management and prevention of progression of these conditions. Cancer 2012;118(8 suppl). © 2012 American Cancer Society.